Skin Infection News and Research

RSS

CPT-F antibiotic drug may hold promise for treating potentially fatal MRSA pneumonia

A drug approved just two years ago for treating bacterial infections may hold promise for treating the potentially fatal MRSA pneumonia, according to a Henry Ford Hospital study.

12 Sep 2013

Incidence of septicemia increasing among service members, study finds

The annual incidence rates of primary diagnosed septicemia among active component service members increased nearly 580 percent from 2004 to 2012, according to a new study.

6 Sep 2013

Hospital readmissions rates for children are not meaningful measures of quality of their care

Readmission rates of adult patients to the same hospital within 30 days are an area of national focus and a potential indicator of clinical failure and unnecessary expenditures.

27 Aug 2013

FDA approves first mass spectrometer system in U.S. for identification of bacteria, yeasts

The U.S. Food and Drug Administration today allowed marketing in the U.S. of the first mass spectrometer system for automated identification of bacteria and yeasts that are known to cause serious illness in humans.

22 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

Physicians prescribe strongest antibiotics capable of killing multiple kinds of bacteria

When U.S. physicians prescribe antibiotics, more than 60 percent of the time they choose some of the strongest types of antibiotics, referred to as "broad spectrum," which are capable of killing multiple kinds of bacteria, University of Utah researchers show in a new study.

2 Aug 2013

Symptoms, first-aid treatments and prevention tips for insect bites

Whether they are invading your picnic, hitching a ride on your skin or just buzzing around your head, bugs are an annoying and unavoidable part of summer. Still, there are times when bugs are just a nuisance and times when they can cause serious illness or injury.

24 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

Orlando Health's clinicians provide hospital-level care in patient's home

Instead of admitting patients to medical units at the hospital, clinicians at Orlando Regional Medical Center are providing health care to patients in the comfort of their homes. The new twist on modern medicine is being piloted in a project to provide hospital-level care in a patient's home through home visits, videoconferencing (virtual visit) and telemonitoring (remote vital signs monitoring).

28 Jun 2013

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019.

4 Jun 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects.

23 May 2013

Certain varieties of clay have ability to kill MRSA, says ASU researcher

In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.

20 May 2013

Sorrento Therapeutics' anti-MRSA program gets NIAID support

Sorrento Therapeutics, Inc. announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including methicillin-resistant S. aureus, was renewed for the second year of a two year Phase I grant award.

18 May 2013

Researchers urge doctors to consider Lyme disease as cause when presented with skin lesions

When a person contracts Lyme disease, quick diagnosis and treatment are essential to avoiding long term complications. But the diagnostic process may be delayed if a physician does not recognize a skin rash caused by Lyme disease because it does not have the bull's-eye appearance that is best known to physicians and the public.

23 Apr 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Researchers ESTABLISH efficacy of tedizolid phosphate for skin infections

Results from the phase III ESTABLISH-1 study show that the new antibiotic tedizolid phosphate is noninferior to linezolid for the treatment of acute bacterial and skin structure infections.

14 Feb 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

Institute of Bioengineering and Nanotechnology, IBM reveal new antimicrobial hydrogel

Researchers from IBM and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact.

24 Jan 2013